GlassScriptPhysician profile
Marco Caccamo
NPI 1164696530
$75,897.29
in general payments reported to CMS, 2019-2025
9 companies · $12K in 2025
The $12K reported for 2025 was more than what 79% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,672 · 2021: $5,593 · 2022: $4,881 · 2023: $20K · 2024: $17K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $14K · Travel and Lodging: $5,614 · Food and Beverage: $1,504 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,794.00 |
| Consulting Fee | $14,210.00 |
| Travel and Lodging | $5,614.32 |
| Food and Beverage | $1,503.82 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $35,671.70 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $28,682.06 | 2023-2025 | Winrevair, Verquvo |
| Actelion Pharmaceuticals US, INC. | $10,725.93 | 2023-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $290.03 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Research & Development, LLC | $285.32 | 2019 | |
| Cvrx, INC. | $162.20 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.61 | 2025 | Lifevest |
| Sandoz INC. | $33.44 | 2023 | Treprostinil |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Caccamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.